Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Remedy Entertainment Oyj is a Finnish video game developer specializing in cinematic, story-driven action games for PC and console platforms. Founded in 1995 by members of the demoscene group Future Crew, the company is headquartered in Espoo, Finland, with an additional studio in Stockholm, Sweden since 2022. It is renowned for creating critically acclaimed franchises including Max Payne, Alan Wake, and Control, which feature strong narratives, immersive worlds, and innovative gameplay powered by its proprietary Northlight engine. Notable titles encompass Quantum Break, Alan Wake 2, and upcoming projects like Control 2 co-produced with Annapurna Pictures, alongside remakes of Max Payne games funded by Rockstar Games. Remedy Entertainment Oyj focuses on single-player experiences with motion capture technology and has expanded into multi-project development, work-for-hire collaborations, and multimedia ventures such as TV adaptations. Employing around 385 professionals, it plays a significant role in the global gaming industry by delivering high-quality, visually stunning titles that emphasize storytelling and player immersion.
€13.88
€0.42 (-2.94%)
EOD Jul 2, 2026
The business is unprofitable at the operating level (-24.98% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 17.5%, still solid. Margins contracted 16.5pp, which offsets some of the top-line progress.
ROIC dropped from -4.34% to -14.75%, capital efficiency is deteriorating. Negative free cash flow of -€10M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€59M
▲ +17.5% YoY
Net Income (TTM)
-€13M
▼ -262.3% YoY
Op. Margin
-25.53%
▼ -16.5pp YoY
ROIC
-14.75%
▼ -10.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€5M
▼ -304.6% YoY
Op. Cash Flow (TTM)
€5M
▼ -304.6% YoY
Net Debt
-€11M
Net Cash Position
Cash & Equiv.
€29M
3Y CAGR: +10.9%
Continue Research
Remedy Entertainment Oyj (REMEDY.XHEL) trades around a two-stage DCF intrinsic value of about €18.07 per share, so at €13.88 the stock looks around fair value (30.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Remedy Entertainment Oyj scores 48/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €18.07 per share for REMEDY.XHEL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €13.55. At today's €13.88, that puts the stock about 30.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Remedy Entertainment Oyj scores 48 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -25.5% operating margin and a -14.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. REMEDY.XHEL currently trades around its estimated intrinsic value and scores 48/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.